Codexis (NASDAQ:CDXS), headquartered in Redwood City, California, is a leading protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications. The company’s proprietary directed evolution platform, CodeEvolver®, enables the rapid identification and optimization of enzymes with enhanced activity, selectivity and stability. By leveraging this technology, Codexis provides custom biocatalysts designed to improve manufacturing efficiency and reduce environmental impact.
Since its founding in 2002, Codexis has expanded its capabilities from early-stage research to commercial-scale production. The company operates advanced research and development laboratories alongside cGMP manufacturing facilities, allowing for seamless scale-up of enzyme processes. Its multidisciplinary team of molecular biologists, biochemists and process engineers collaborates closely with clients to integrate tailored enzyme solutions into existing production workflows.
Codexis’s biocatalysts have been applied to the synthesis of active pharmaceutical ingredients, delivering streamlined routes and cost reductions in drug manufacturing. Beyond pharmaceuticals, the company addresses challenges in the food and beverage sector—such as flavor enhancement and ingredient processing—and in the fine chemicals and agricultural markets. Codexis’s commitment to sustainable biocatalysis supports industry efforts toward greener chemistry and resource conservation.
Serving a global customer base, Codexis engages in partnerships and licensing arrangements with leading industrial and pharmaceutical organizations. Its commercial model typically combines research funding, milestone payments and royalty streams, positioning the company for diversified revenue growth across multiple projects. With an emphasis on innovation and environmental stewardship, Codexis continues to drive advancements in the burgeoning field of enzyme-based manufacturing.
